Drug Trial Radar · NCT07903623
QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 25, 2026
Primary completion
Dec 30, 2029
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination. The main questions it aims to answer are: * How many participants achieve measurable residual disease (MRD) negativity after 9 treatment cycles? * What side effects occur during treatment with QLS4131 combined with isatuximab? * How many participants respond to treatment, and how many achieve a complete response? * How many participants achieve sustained MRD negativity? * How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study. Participants will: * Receive QLS4131 by subcutaneous injection together with intravenous isatuximab in 28-day treatment cycles. * Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety. * Undergo peripheral blood stem cell mobilization and collection after the first 3 treatment cycles, if appropriate. * Be monitored throughout the study for side effects, including adverse events and serious adverse events.
Conditions
- Primary Plasma Cell Leukemia
Interventions
QLS4131Drug
QLS4131 is administered subcutaneously (SC) using a step-up dosing regimen, followed by a target dose of 12 mg. During Cycle 1, QLS4131 is administered every 2 weeks; from Cycle 2 through Cycle 18, it is administered every 4 weeks.
IsatuximabDrug
Isatuximab is administered intravenously (IV) at 10 mg/kg. It is given weekly during Cycle 1, every 2 weeks during Cycles 2-12, and every 4 weeks during Cycles 13-18.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal residual disease (MRD) negative rateTime frame: After 9 cycles (each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.